Johnson & Johnson's (JNJ -0.8%) Janssen Research & Development unit says the FDA has...

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

Johnson & Johnson's (JNJ -0.8%) Janssen Research & Development unit says the FDA has rejected the approval of its blood thinner Xarelto as oral anticoagulant used to reduce the risk of stent thrombosis in patients with acute coronary syndrome. Since aprroving the drug in July 2011, the agency has expanded its use for treating certain blood clots and reducing their recurrence, and is currently approved for six clinical uses in the United States. Xarelto is co-marketed by JNJ and Bayer (BAYRY.PK)